LitCovid-sample-Enju  

PMC:7205724 / 607-1761 JSONTXT 22 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
T92 0-3 DT denotes The
T93 4-9 JJ denotes novel
T94 10-21 NN denotes coronavirus
T95 21-22 -COMMA- denotes ,
T96 23-32 NN denotes SARS-CoV2
T97 32-33 -COMMA- denotes ,
T98 34-37 MD denotes can
T99 38-43 VB denotes cause
T100 44-45 DT denotes a
T101 46-57 RB denotes potentially
T102 58-63 JJ denotes fatal
T103 64-71 NN denotes disease
T104 71-72 -COMMA- denotes ,
T105 73-81 NN denotes COVID-19
T106 81-82 -COMMA- denotes ,
T107 83-85 IN denotes in
T108 86-92 NNS denotes humans
T109 94-98 RB denotes Here
T110 98-99 -COMMA- denotes ,
T111 100-102 PRP denotes we
T112 103-107 MD denotes will
T113 108-115 VB denotes provide
T114 116-118 DT denotes an
T115 119-127 NN denotes overview
T116 128-130 IN denotes of
T117 131-142 JJ denotes therapeutic
T118 143-150 NNS denotes options
T119 151-154 IN denotes for
T120 155-163 NN denotes COVID-19
T121 165-171 NN denotes Plasma
T122 172-176 IN denotes from
T123 177-185 NNS denotes patients
T124 186-195 VBN denotes recovered
T125 196-200 IN denotes from
T126 201-209 NN denotes COVID-19
T127 210-214 WDT denotes that
T128 215-223 VBZ denotes contains
T129 224-234 NNS denotes antibodies
T130 235-242 IN denotes against
T131 243-252 NN denotes SARS-CoV2
T132 253-256 VBZ denotes has
T133 257-262 VBN denotes shown
T134 263-272 JJ denotes promising
T135 273-280 NNS denotes results
T136 281-283 IN denotes in
T137 284-292 NNS denotes patients
T138 293-297 IN denotes with
T139 298-304 JJ denotes severe
T140 305-313 NN denotes COVID-19
T141 315-319 RB denotes Also
T142 319-320 -COMMA- denotes ,
T143 321-325 NNP denotes IVIG
T144 325-326 -COMMA- denotes ,
T145 327-335 VBN denotes combined
T146 336-340 IN denotes with
T147 341-354 NN denotes moderate-dose
T148 355-357 IN denotes of
T149 358-373 NNS denotes corticosteroids
T150 373-374 -COMMA- denotes ,
T151 375-380 MD denotes might
T152 381-388 VB denotes improve
T153 389-396 NN denotes patient
T154 397-405 NNS denotes outcomes
T155 407-415 NN denotes Evidence
T156 416-421 VBZ denotes links
T157 422-430 NN denotes COVID-19
T158 431-433 TO denotes to
T159 434-442 JJ denotes variable
T160 443-450 NNS denotes degrees
T161 451-453 IN denotes of
T162 454-466 NN denotes inflammation
T163 468-475 NNS denotes Studies
T164 476-480 VBP denotes show
T165 481-485 IN denotes that
T166 486-489 DT denotes the
T167 490-493 NN denotes use
T168 494-496 IN denotes of
T169 497-512 NNS denotes corticosteroids
T170 513-518 MD denotes might
T171 519-529 VB denotes accelerate
T172 530-538 NN denotes recovery
T173 539-543 IN denotes from
T174 544-552 NN denotes COVID-19
T175 554-559 EX denotes There
T176 560-563 VBP denotes are
T177 563-564 -COMMA- denotes ,
T178 565-572 RB denotes however
T179 572-573 -COMMA- denotes ,
T180 574-576 DT denotes no
T181 577-587 JJ denotes controlled
T182 588-596 JJ denotes clinical
T183 597-603 NNS denotes trials
T184 604-608 WDT denotes that
T185 609-613 VBP denotes show
T186 614-621 IN denotes whether
T187 622-625 DT denotes the
T188 626-629 NN denotes use
T189 630-632 IN denotes of
T190 633-648 NNS denotes corticosteroids
T191 649-652 MD denotes can
T192 653-659 VB denotes reduce
T193 660-676 JJ denotes COVID-19-related
T194 677-682 NN denotes death
T195 684-688 RB denotes Also
T196 688-689 -COMMA- denotes ,
T197 690-693 DT denotes the
T198 694-710 JJ denotes pro-inflammatory
T199 711-719 NN denotes cytokine
T200 720-723 NN denotes IL6
T201 724-726 VBZ denotes is
T202 727-730 DT denotes the
T203 731-746 JJ denotes best-documented
T204 747-755 NN denotes cytokine
T205 756-758 IN denotes in
T206 759-767 NN denotes COVID-19
T207 768-778 VBD denotes correlated
T208 779-783 IN denotes with
T209 784-792 NN denotes severity
T210 792-793 -COMMA- denotes ,
T211 794-805 NN denotes criticality
T212 805-806 -COMMA- denotes ,
T213 807-812 JJ denotes viral
T214 813-817 NN denotes load
T215 817-818 -COMMA- denotes ,
T216 819-822 CC denotes and
T217 823-832 NN denotes prognosis
T218 833-835 IN denotes of
T219 836-844 NNS denotes patients
T220 845-849 IN denotes with
T221 850-858 NN denotes COVID-19
T222 860-871 NNP denotes Tocilizumab
T223 871-872 -COMMA- denotes ,
T224 873-874 DT denotes a
T225 875-885 JJ denotes monoclonal
T226 886-894 NN denotes antibody
T227 895-902 IN denotes against
T228 903-906 NN denotes IL6
T229 906-907 -COMMA- denotes ,
T230 908-913 MD denotes could
T231 914-920 VB denotes confer
T232 921-929 JJ denotes clinical
T233 930-937 NN denotes benefit
T234 938-940 IN denotes in
T235 941-949 NNS denotes patients
T236 950-954 IN denotes with
T237 955-959 JJ denotes high
T238 960-963 NN denotes IL6
T239 964-970 NNS denotes levels
T240 972-981 JJ denotes Essential
T241 982-990 NNS denotes elements
T242 991-995 IN denotes that
T243 996-1003 NN denotes process
T244 1004-1013 NN denotes SARS-CoV2
T245 1014-1018 NN denotes cell
T246 1019-1024 NN denotes entry
T247 1025-1028 CC denotes and
T248 1029-1037 JJ denotes specific
T249 1038-1053 NNS denotes characteristics
T250 1054-1058 WDT denotes that
T251 1059-1064 VBP denotes allow
T252 1065-1074 NN denotes SARS-CoV2
T253 1075-1077 TO denotes to
T254 1078-1084 VB denotes escape
T255 1085-1088 DT denotes the
T256 1089-1095 JJ denotes immune
T257 1096-1102 NN denotes system
T258 1103-1107 VBP denotes have
T259 1108-1111 DT denotes the
T260 1112-1121 NN denotes potential
T261 1122-1124 IN denotes as
T262 1125-1132 NNS denotes targets
T263 1133-1136 IN denotes for
T264 1137-1145 NN denotes COVID-19
T265 1146-1153 NN denotes therapy
R100 T99 T107 arg1Of cause,in
R101 T108 T107 arg2Of humans,in
R102 T113 T109 arg1Of provide,Here
R103 T113 T110 arg1Of provide,","
R104 T111 T112 arg1Of we,will
R105 T113 T112 arg2Of provide,will
R106 T111 T113 arg1Of we,provide
R107 T115 T113 arg2Of overview,provide
R108 T115 T114 arg1Of overview,an
R109 T115 T116 arg1Of overview,of
R110 T118 T116 arg2Of options,of
R111 T118 T117 arg1Of options,therapeutic
R112 T115 T119 arg1Of overview,for
R113 T120 T119 arg2Of COVID-19,for
R114 T121 T122 arg1Of Plasma,from
R115 T123 T122 arg2Of patients,from
R116 T123 T124 arg2Of patients,recovered
R117 T124 T125 arg1Of recovered,from
R118 T126 T125 arg2Of COVID-19,from
R119 T126 T127 arg1Of COVID-19,that
R120 T126 T128 arg1Of COVID-19,contains
R121 T129 T128 arg2Of antibodies,contains
R122 T129 T130 arg1Of antibodies,against
R123 T131 T130 arg2Of SARS-CoV2,against
R124 T121 T132 arg1Of Plasma,has
R125 T133 T132 arg2Of shown,has
R126 T121 T133 arg1Of Plasma,shown
R127 T135 T133 arg2Of results,shown
R128 T135 T134 arg1Of results,promising
R129 T133 T136 arg1Of shown,in
R130 T137 T136 arg2Of patients,in
R131 T137 T138 arg1Of patients,with
R132 T140 T138 arg2Of COVID-19,with
R133 T140 T139 arg1Of COVID-19,severe
R134 T152 T141 arg1Of improve,Also
R135 T152 T142 arg1Of improve,","
R136 T143 T144 arg1Of IVIG,","
R137 T143 T145 arg2Of IVIG,combined
R138 T145 T146 arg1Of combined,with
R139 T147 T146 arg2Of moderate-dose,with
R140 T147 T148 arg1Of moderate-dose,of
R141 T149 T148 arg2Of corticosteroids,of
R142 T152 T150 arg1Of improve,","
R143 T143 T151 arg1Of IVIG,might
R144 T152 T151 arg2Of improve,might
R145 T143 T152 arg1Of IVIG,improve
R146 T154 T152 arg2Of outcomes,improve
R147 T154 T153 arg1Of outcomes,patient
R148 T155 T156 arg1Of Evidence,links
R149 T157 T156 arg2Of COVID-19,links
R150 T156 T158 arg1Of links,to
R151 T160 T158 arg2Of degrees,to
R152 T160 T159 arg1Of degrees,variable
R153 T160 T161 arg1Of degrees,of
R154 T162 T161 arg2Of inflammation,of
R155 T163 T164 arg1Of Studies,show
R156 T171 T164 arg2Of accelerate,show
R157 T171 T165 arg1Of accelerate,that
R158 T167 T166 arg1Of use,the
R159 T167 T168 arg1Of use,of
R160 T169 T168 arg2Of corticosteroids,of
R161 T167 T170 arg1Of use,might
R162 T171 T170 arg2Of accelerate,might
R163 T167 T171 arg1Of use,accelerate
R164 T172 T171 arg2Of recovery,accelerate
R165 T172 T173 arg1Of recovery,from
R166 T174 T173 arg2Of COVID-19,from
R167 T175 T176 arg1Of There,are
R168 T183 T176 arg2Of trials,are
R169 T176 T177 arg1Of are,","
R170 T176 T178 arg1Of are,however
R171 T176 T179 arg1Of are,","
R172 T183 T180 arg1Of trials,no
R173 T182 T181 arg1Of clinical,controlled
R174 T183 T182 arg1Of trials,clinical
R175 T183 T184 arg1Of trials,that
R176 T183 T185 arg1Of trials,show
R177 T192 T185 arg2Of reduce,show
R178 T192 T186 arg1Of reduce,whether
R179 T188 T187 arg1Of use,the
R180 T188 T189 arg1Of use,of
R181 T190 T189 arg2Of corticosteroids,of
R182 T188 T191 arg1Of use,can
R183 T192 T191 arg2Of reduce,can
R184 T188 T192 arg1Of use,reduce
R185 T194 T192 arg2Of death,reduce
R186 T194 T193 arg1Of death,COVID-19-related
R187 T201 T195 arg1Of is,Also
R188 T201 T196 arg1Of is,","
R189 T200 T197 arg1Of IL6,the
R190 T200 T198 arg1Of IL6,pro-inflammatory
R191 T200 T199 arg1Of IL6,cytokine
R192 T200 T201 arg1Of IL6,is
R193 T204 T201 arg2Of cytokine,is
R194 T204 T202 arg1Of cytokine,the
R195 T204 T203 arg1Of cytokine,best-documented
R196 T204 T205 arg1Of cytokine,in
R197 T216 T205 arg2Of and,in
R198 T206 T207 arg2Of COVID-19,correlated
R199 T207 T208 arg1Of correlated,with
R200 T209 T208 arg2Of severity,with
R201 T209 T210 arg1Of severity,","
R202 T211 T210 arg2Of criticality,","
R203 T206 T212 arg1Of COVID-19,","
R204 T214 T212 arg2Of load,","
R205 T214 T213 arg1Of load,viral
R206 T216 T215 arg1Of and,","
R207 T212 T216 arg1Of ",",and
R208 T217 T216 arg2Of prognosis,and
R209 T217 T218 arg1Of prognosis,of
R210 T219 T218 arg2Of patients,of
R211 T219 T220 arg1Of patients,with
R212 T221 T220 arg2Of COVID-19,with
R213 T222 T223 arg1Of Tocilizumab,","
R214 T226 T223 arg2Of antibody,","
R215 T226 T224 arg1Of antibody,a
R216 T226 T225 arg1Of antibody,monoclonal
R217 T226 T227 arg1Of antibody,against
R218 T228 T227 arg2Of IL6,against
R219 T231 T229 arg1Of confer,","
R220 T222 T230 arg1Of Tocilizumab,could
R221 T231 T230 arg2Of confer,could
R222 T222 T231 arg1Of Tocilizumab,confer
R223 T233 T231 arg2Of benefit,confer
R224 T233 T232 arg1Of benefit,clinical
R225 T231 T234 arg1Of confer,in
R226 T235 T234 arg2Of patients,in
R227 T235 T236 arg1Of patients,with
R228 T239 T236 arg2Of levels,with
R229 T239 T237 arg1Of levels,high
R230 T239 T238 arg1Of levels,IL6
R231 T241 T240 arg1Of elements,Essential
R232 T241 T242 arg1Of elements,that
R233 T247 T242 arg2Of and,that
R234 T258 T242 arg3Of have,that
R235 T246 T243 arg1Of entry,process
R236 T246 T244 arg1Of entry,SARS-CoV2
R237 T246 T245 arg1Of entry,cell
R238 T246 T247 arg1Of entry,and
R239 T249 T247 arg2Of characteristics,and
R240 T249 T248 arg1Of characteristics,specific
R241 T249 T250 arg1Of characteristics,that
R242 T249 T251 arg1Of characteristics,allow
R243 T252 T251 arg2Of SARS-CoV2,allow
R244 T254 T251 arg3Of escape,allow
R245 T254 T253 arg1Of escape,to
R246 T252 T254 arg1Of SARS-CoV2,escape
R247 T257 T254 arg2Of system,escape
R248 T257 T255 arg1Of system,the
R249 T257 T256 arg1Of system,immune
R250 T247 T258 arg1Of and,have
R251 T260 T258 arg2Of potential,have
R252 T260 T259 arg1Of potential,the
R253 T258 T261 arg1Of have,as
R254 T262 T261 arg2Of targets,as
R255 T262 T263 arg1Of targets,for
R256 T265 T263 arg2Of therapy,for
R257 T265 T264 arg1Of therapy,COVID-19
R85 T94 T92 arg1Of coronavirus,The
R86 T94 T93 arg1Of coronavirus,novel
R87 T94 T95 arg1Of coronavirus,","
R88 T96 T95 arg2Of SARS-CoV2,","
R89 T99 T97 arg1Of cause,","
R90 T94 T98 arg1Of coronavirus,can
R91 T99 T98 arg2Of cause,can
R92 T94 T99 arg1Of coronavirus,cause
R93 T103 T99 arg2Of disease,cause
R94 T103 T100 arg1Of disease,a
R95 T102 T101 arg1Of fatal,potentially
R96 T103 T102 arg1Of disease,fatal
R97 T103 T104 arg1Of disease,","
R98 T105 T104 arg2Of COVID-19,","
R99 T99 T106 arg1Of cause,","